ERYTECH presenta le sue conclusioni in occasione del meeting della European Red Cell Research Society

NEXT STORY
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
PREV STORY
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), ...

author_avatar
NASDAQ Market News

KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)

author_avatar
NASDAQ Market News

Checkmate Pharmaceuticals Presents Updated Clinical Data with CMP-001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

author_avatar
NASDAQ Market News